Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro

Wojciech Filipiak, Andreas Sponring, Tomas Mikoviny, Clemens Ager, Jochen Schubert, Wolfram Miekisch, Anton Amann, Jakob Troppmair, Wojciech Filipiak, Andreas Sponring, Tomas Mikoviny, Clemens Ager, Jochen Schubert, Wolfram Miekisch, Anton Amann, Jakob Troppmair

Abstract

Background: The aim of this work was to confirm the existence of volatile organic compounds (VOCs) specifically released or consumed by lung cancer cells.

Methods: 50 million cells of the human non-small cell lung cancer (NSCLC) cell line CALU-1 were incubated in a sealed fermenter for 4 h or over night (18 hours). Then air samples from the headspace of the culture vessel were collected and preconcentrated by adsorption on solid sorbents with subsequent thermodesorption and analysis by means of gas chromatography mass spectrometry (GC-MS). Identification of altogether 60 compounds in GCMS measurement was done not only by spectral library match, but also by determination of retention times established with calibration mixtures of the respective pure compounds.

Results: The results showed a significant increase in the concentrations of 2,3,3-trimethylpentane, 2,3,5-trimethylhexane, 2,4-dimethylheptane and 4-methyloctane in the headspace of CALU-1 cell culture as compared to medium controls after 18 h. Decreased concentrations after 18 h of incubation were found for acetaldehyde, 3-methylbutanal, butyl acetate, acetonitrile, acrolein, methacrolein, 2-methylpropanal, 2-butanone, 2-methoxy-2-methylpropane, 2-ethoxy-2-methylpropane, and hexanal.

Conclusion: Our findings demonstrate that certain volatile compounds can be cancer-cell derived and thus indicative of the presence of a tumor, whereas other compounds are not released but seem to be consumed by CALU-1 cells.

Figures

Figure 1
Figure 1
An exemplary chromatogram of volatile compounds in headspace of the cancer cells CALU-1. 200 ml of headspace from cells cultured in 100 ml medium were collected on a sorption trap filled with Tenax TA, Carboxen 569, Carboxen 1000 and subsequently thermal desorbed into the GC-MS system. The peaks that correspond to compounds discussed in this paper are labeled with letters (see Table 1). Peaks exceeding the range of scale are cut off.
Figure 2
Figure 2
Comparison of VOCs concentrations present at higher concentration in the headspace of CALU-1 cells in culture (blue columns) as compared to medium control (red columns) after 18 h of incubation. Presented are average concentrations (n = 3) with standard deviations. Significant differences are labeled with asterisks.
Figure 4
Figure 4
A and B: Comparison of VOCs concentrations present at lower level in the headspace of cell culture (CALU-1) solution (blue columns) as compared with medium only (red columns) after 4 h (Fig. 4A) and 18 h (Fig. 4B) of incubation. Presented are average concentrations (n = 4 for 4 h of incubation, n = 3 for 18 h of incubation) with standard deviation. Significant differences are labeled with asterisks.
Figure 3
Figure 3
Comparison of VOCs present at lower concentrations present in the headspace of cells in culture (CALU-1) (bright blue and dark blue columns) as compared to medium control (yellow and red columns) after 4 h and 18 h of incubation. Presented are average concentrations (n = 4 for 4 h of incubation, n = 3 for 18 h of incubation) with standard deviations. Significant differences are labeled with asterisks.

References

    1. Amann A, Smith D, (eds) Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Singapore: World Scientific; 2005.
    1. Amann A, Spanel P, Smith D. Breath analysis: the approach towards clinical applications. Mini Rev Med Chem. 2007;7:115–129.
    1. Schubert J, Miekisch W, Nöldge-Schomburg G. VOC breath markers in critically ill patients: potentials and limitations. In: Amann A, Smith D, editor. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Singapore: World Scientific; 2005. pp. 267–292.
    1. Risby T. Current status of clinical breath analysis. In: Amann A, Smith D, editor. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Singapore: World Scientific; 2005. pp. 251–265.
    1. Schubert JK, Miekisch W, Geiger K, Noldge-Schomburg GF. Breath analysis in critically ill patients: potential and limitations. Expert Rev Mol Diagn. 2004;4:619–629.
    1. Davies S, Spanel P, Smith D. A new 'online' method to measure increased exhaled isoprene in end-stage renal failure. Nephrol Dial Transplant. 2001;16:836–839.
    1. Davies S, Spanel P, Smith D. Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. Kidney Int. 1997;52:223–228.
    1. Davies SJ, Spanel P, Smith D. Quantitative analysis of metabolites on the breath of patients in renal failure. Journal of the American Society of Nephrology. 1996;7:A0352–A0352.
    1. Perri F, Marras RM, Ricciardi R, Quitadamo M, Andriulli A. 13C-breath tests in hepatology (cytosolic liver function) Eur Rev Med Pharmacol Sci. 2004;8:47–49.
    1. Candelli M, Armuzzi A, Nista EC, Fini L, Gasbarrini G, Gasbarrini A. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment Pharmacol Ther. 2004;19:243.
    1. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 2007;3:95–109.
    1. Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN. Detection of lung cancer with volatile markers in the breath. Chest. 2003;123:2115–2123.
    1. Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Rahbari-Oskoui F, Wong C. Volatile markers of breast cancer in the breath. Breast J. 2003;9:184–191.
    1. Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, Grabmer C, Gastl G, Amann A. Lung cancer detection by proton transfer reaction mass spectrometric analysis of human breath gas. Int J Mass Spec. 2007;265:49–59.
    1. Machado RF, Laskowski D, Deffenderfer O, Burch T, Zheng S, Mazzone PJ, Mekhail T, Jennings C, Stoller JK, Pyle J, Duncan J, Dweik RA, Erzurum SC. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med. 2005;171:1286–1291.
    1. Di Natale C, Macagnano A, Martinelli E, Paolesse R, D'Arcangelo G, Roscioni C, Finazzi-Agro A, D'Amico A. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron. 2003;18:1209–1218.
    1. Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res. 2005;6:71.
    1. Amann A, Telser S, Hofer L, Schmid A, Hinterhuber H. Exhaled breath as a biochemical probe during sleep. In: Amann A, Smith D, editor. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Singapore: World Scientific; 2005. pp. 305–316.
    1. Smith D, Spanel P. On-line determination of the deuterium abundance in breath water vapour by flowing afterglow mass spectrometry with applications to measurements of total body water. Rapid Commun Mass Spectrom. 2001;15:25–32.
    1. Smith D, Spanel P. On-line determination of the deuterium abundance in breath water vapour by flowing afterglow mass spectrometry, FA-MS, with applications to measurements of total body water. Rapid Commun Mass Spectrom. 2001;15:25–32.
    1. Smith D, Wang TS, Spanel P. On-line, simultaneous quantification of ethanol, some metabolites and water vapour in breath following the ingestion of alcohol. Physiological Measurement. 2002;23:477–489.
    1. Smith D, Wang T, Sule-Suso J, Spanel P, Haj AE. Quantification of acetaldehyde released by lung cancer cells in vitro using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom. 2003;17:845–850.
    1. Homann N. Alcohol and upper gastrointestinal tract cancer: the role of local acetaldehyde production. Addiction biology. 2001;6:309–323.
    1. Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1:485–487.
    1. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH, Yoo YJ. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun. 2001;289:507–512.
    1. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008;59:340–349.

Source: PubMed

3
구독하다